Vera Therapeutics (VERA) CRO Nancy Boman Receives Award

What Happened Nancy Lee Boman, Chief Regulatory Officer of Vera Therapeutics (VERA), was granted equity awards on August 3, 2026: 44,987 restricted stock units (RSUs) and a derivative award covering 63,011 shares. Both grants were recorded at $0.00 (no cash paid) and therefore have a total reported acquisition value of $0 on the Form 4.

Key Details

• Transaction date: August 3, 2026; Filing date: August 5, 2026 (timely Form 4 filing).
• Grant details:
  • 44,987 RSUs (Class A common stock) — reported as an award at $0.00.
  • 63,011-share derivative award (reported as an acquisition/derivative) — $0.00.
• Vesting/termination notes:
  • RSUs: 1/4th vest (rounded to nearest share) on each of Aug 20, 2027, 2028, 2029 and 2030, subject to continued service. (Footnote F1)
  • Derivative award: 12/48ths vest on Aug 3, 2027, then 1/48th vests monthly on the same day thereafter, subject to continued service. (Footnote F2)
• Shares owned after the transaction: not specified in the provided filing details.
• No indication of a 10b5-1 plan, sale, or tax-withholding in the reported items.

Context These entries are awards (compensation/retention grants), not purchases or sales, and therefore represent potential future economic interest subject to vesting conditions rather than immediate stock ownership or proceeds. They do not by themselves indicate insider buying or selling intent; vesting is conditioned on continued service.